Last reviewed · How we verify

Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd. — Portfolio Competitive Intelligence Brief

Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd. pipeline: 0 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
DAG181 DAG181 phase 3 PD-L1 inhibitor PD-L1 Oncology
TG-2349 TG-2349 phase 3 SGLT2 inhibitor SGLT2 Diabetes

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Qilu Pharmaceutical Co., Ltd. · 2 shared drug classes
  2. AstraZeneca · 2 shared drug classes
  3. GlaxoSmithKline · 2 shared drug classes
  4. Green Cross Corporation · 2 shared drug classes
  5. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · 2 shared drug classes
  6. AceLink Therapeutics, Inc. · 1 shared drug class
  7. Abbott · 1 shared drug class
  8. ADvantage Therapeutics · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.:

Cite this brief

Drug Landscape (2026). Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/dongguan-hec-taigen-biopharmaceuticals-co-ltd. Accessed 2026-05-17.

Related